N-[(4R)-2-oxo-4-phenylpyrrolidin-1-yl]acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-[(4R)-2-oxo-4-phenylpyrrolidin-1-yl]acetamide
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.25
• InChiKey: IPDBSNCCOYLXED-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PHARMACEUTICAL SUBSTANCE (VARIANTS) AND COMPOSITIONS BASED THEREON WHICH EXHIBIT MODULATORY ACTIVITY WITH A COMMENSURATE EFFECT
  申请人：Akhapkina, Valentina Ivanovna

  公开号：EP2762138A1

  公开（公告）日：2014-08-06

  The invention relates to various fields of medicine, pharmaceutics and pharmacology, chemico-pharmaceutical, pharmaceutical and para-pharmaceutical industries, and in particular to new class of agents having modulatory activity with commensurate effect. The invention consists in that provided product (RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide does not contain biologically inert substances in its composition having adverse effect on its newly discovered and considerably improved known properties and characteristics, at the same time discovering unknown before vitally important and essential ideas about the composition, widening the field of its application while increasing its efficiency and safety of use, increasing its therapeutic scope, provides for preparing the product and its products with revealed properties and characteristics.

  本发明涉及医学、药剂学和药理学、化学制药、制药和准制药工业的各个领域，特别是涉及具有相应效果的调节活性的新型制剂。本发明在于所提供的(RS)-2-(2-氧代-4-苯基吡咯烷-1-基)乙酰胺产品在其组成中不含有对其新发现的和大大改进的已知性质和特征有不利影响的生物惰性物质，同时发现了有关该组成的极为重要和必要的想法，拓宽了其应用领域，同时提高了其使用效率和安全性，扩大了其治疗范围，提供了制备具有所揭示的性质和特征的产品及其制品的方法。
• RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide compound having modulatory activity with a commensurate effect, pharmaceutical substance (variants) and its application, composition (variants) thereof
  申请人：Akhapkina Valentina Ivanovna

  公开号：US20140315972A1

  公开（公告）日：2014-10-23

  The invention relates to a compound (RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide having modulatory activity with a commensurate effect, to a pharmaceutical substance (RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide containing: 2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide—no less than 99.0% and no more than 100.5% on dry basis, individual related impurities individually or in total—no more than 0.2%; residual amounts of organic solvents individually or in total—no more than 3000 ppm. The invention also relates to a method for producing the pharmaceutical substance differing in that the obtained raw materials are subjected to purification, crystallization and stabilization of the compound by processing it with demineralized (distilled) water, and the isothermal crystallization from propanol followed by drying. The invention also relates to compositions for internal and external application. The invention provides higher efficacy, safety, stability and width of therapeutic application. 55 cl, 3 dwg, 80 tbl, 27 ex.